Jan 2 (Reuters) - Mesoblast Ltd MSB.AX :
* MESOBLAST SUBMITS CLINICAL EFFICACY AND SAFETY DATA TO FDA IN ROLLING BIOLOGICS LICENSE APPLICATION FOR REMESTEMCEL-L
* MESOBLAST LTD - IF APPROVED, REMESTEMCEL-L IS PLANNED TO BE LAUNCHED IN US IN 2020
* MESOBLAST LTD - WILL REQUEST EXPEDITED FDA REVIEW OF BLA FOR REMESTEMCEL-L UNDER PRODUCT CANDIDATE'S EXISTING FAST TRACK DESIGNATION